Replies to post #3891 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

[Wheeler] thinks that the [Lovenox] market is too big not to be attractive to a wide range of competitors.

The counter-argument is that Teva and Amphastar have been unable to get FDA approval despite trying for eight years. One would think such a track record would put a damper on the eagerness for other applicants to give it a try.